Pacific Biosciences of California (NASDAQ:PACB) — Market Cap & Net Worth
Market Cap & Net Worth: Pacific Biosciences of California (PACB)
Pacific Biosciences of California (NASDAQ:PACB) has a market capitalization of $400.97 Million ($400.97 Million) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #13443 globally and #3260 in its home market, demonstrating a -0.74% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pacific Biosciences of California's stock price $1.34 by its total outstanding shares 310830759 (310.83 Million). Also see PACB asset base for a full breakdown of the balance sheet.
Pacific Biosciences of California Market Cap History: 2015 to 2026
Pacific Biosciences of California's market capitalization history from 2015 to 2026. Data shows change from $4.08 Billion to $416.51 Million (-14.70% CAGR). Also see Pacific Biosciences of California (PACB) cash flow conversion for how efficiently the company converts equity into cash flow.
Index Memberships
Pacific Biosciences of California is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.02% | #366 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.00% | #1313 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.02% | #201 of 263 |
Weight: Pacific Biosciences of California's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Pacific Biosciences of California Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pacific Biosciences of California's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check PACB share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
3.63x
Pacific Biosciences of California's market cap is 3.63 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.18 Billion | $90.71 Million | -$74.38 Million | 13.02x | N/A |
| 2017 | $820.59 Million | $93.47 Million | -$92.19 Million | 8.78x | N/A |
| 2018 | $2.30 Billion | $78.63 Million | -$102.56 Million | 29.25x | N/A |
| 2019 | $1.60 Billion | $90.89 Million | -$84.13 Million | 17.58x | N/A |
| 2020 | $8.06 Billion | $78.89 Million | $29.40 Million | 102.20x | 274.22x |
| 2021 | $6.36 Billion | $130.51 Million | -$181.22 Million | 48.73x | N/A |
| 2022 | $2.54 Billion | $128.30 Million | -$314.25 Million | 19.82x | N/A |
| 2023 | $3.05 Billion | $200.52 Million | -$306.74 Million | 15.21x | N/A |
| 2024 | $568.82 Million | $154.01 Million | -$309.85 Million | 3.69x | N/A |
| 2025 | $581.25 Million | $160.00 Million | -$546.38 Million | 3.63x | N/A |
Competitor Companies of PACB by Market Capitalization
Companies near Pacific Biosciences of California in the global market cap rankings as of September 17, 2026. Review Pacific Biosciences of California (PACB) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Pacific Biosciences of California by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #125 globally with a market cap of $177.42 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #229 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #232 globally with a market cap of $107.98 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #239 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #125 | Abbott Laboratories | NYSE:ABT | $177.42 Billion | $102.03 |
| #229 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $93.75 |
| #232 | Stryker Corporation | NYSE:SYK | $107.98 Billion | $281.50 |
| #239 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Pacific Biosciences of California Historical Marketcap From 2015 to 2026
Between 2015 and today, Pacific Biosciences of California's market cap moved from $4.08 Billion to $ 416.51 Million, with a yearly change of -14.70%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $416.51 Million | -28.34% |
| 2025 | $581.25 Million | +2.19% |
| 2024 | $568.82 Million | -81.35% |
| 2023 | $3.05 Billion | +19.93% |
| 2022 | $2.54 Billion | -60.02% |
| 2021 | $6.36 Billion | -21.13% |
| 2020 | $8.06 Billion | +404.67% |
| 2019 | $1.60 Billion | -30.54% |
| 2018 | $2.30 Billion | +180.30% |
| 2017 | $820.59 Million | -30.53% |
| 2016 | $1.18 Billion | -71.06% |
| 2015 | $4.08 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Pacific Biosciences of California was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $400.97 Million USD |
| MoneyControl | $400.97 Million USD |
| MarketWatch | $400.97 Million USD |
| marketcap.company | $400.97 Million USD |
| Reuters | $400.97 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pacific Biosciences of California
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stran… Read more